Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,209.13 -13.71 (-0.02%) CMC Crypto 200
1,373.36 -44.51 (-3.14%)
FOLD Jan 2025 8.000 call
| Previous close | 2.4500 |
| Open | 2.4500 |
| Bid | 2.4500 |
| Ask | 3.6000 |
| Strike | 8.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.4500 - 2.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 360 |
Simply Wall St.Investors in Amicus Therapeutics (NASDAQ:FOLD) from a year ago are still down 19%, even after 3.9% gain this past week
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
GlobeNewswireAmicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therape
- GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product to Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat). The prestigious Prix Galien is awarded to companies recognized for their outstanding advances in the discov
